332 related articles for article (PubMed ID: 27512874)
1. Comparative efficacy of interventions on nonalcoholic fatty liver disease (NAFLD): A PRISMA-compliant systematic review and network meta-analysis.
Sawangjit R; Chongmelaxme B; Phisalprapa P; Saokaew S; Thakkinstian A; Kowdley KV; Chaiyakunapruk N
Medicine (Baltimore); 2016 Aug; 95(32):e4529. PubMed ID: 27512874
[TBL] [Abstract][Full Text] [Related]
2. Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: A systematic review and network meta-analysis.
Singh S; Khera R; Allen AM; Murad MH; Loomba R
Hepatology; 2015 Nov; 62(5):1417-32. PubMed ID: 26189925
[TBL] [Abstract][Full Text] [Related]
3. Meta-Analysis of Randomized Controlled Trials of Pharmacologic Agents in Non-alcoholic Steatohepatitis.
Said A; Akhter A
Ann Hepatol; 2017; 16(4):538-547. PubMed ID: 28611274
[TBL] [Abstract][Full Text] [Related]
4. Improvements in Histologic Features and Diagnosis Associated With Improvement in Fibrosis in Nonalcoholic Steatohepatitis: Results From the Nonalcoholic Steatohepatitis Clinical Research Network Treatment Trials.
Brunt EM; Kleiner DE; Wilson LA; Sanyal AJ; Neuschwander-Tetri BA;
Hepatology; 2019 Aug; 70(2):522-531. PubMed ID: 30549292
[TBL] [Abstract][Full Text] [Related]
5. The effect and safety of obeticholic acid for patients with nonalcoholic steatohepatitis: A systematic review and meta-analysis of randomized controlled trials.
Zhao J; Li B; Zhang K; Zhu Z
Medicine (Baltimore); 2024 Feb; 103(7):e37271. PubMed ID: 38363900
[TBL] [Abstract][Full Text] [Related]
6. Emerging role of obeticholic acid in the management of nonalcoholic fatty liver disease.
Makri E; Cholongitas E; Tziomalos K
World J Gastroenterol; 2016 Nov; 22(41):9039-9043. PubMed ID: 27895393
[TBL] [Abstract][Full Text] [Related]
7. Comparative Efficacy of Drug Interventions on NAFLD Over 24 Weeks: A Traditional and Network Meta-Analysis of Randomized Controlled Trials.
Wang Y; Yi H; Sun W; Yu H; Tao W; Yu X; Jia D; Liu Y; Pandol SJ; Li L
Drugs; 2024 Apr; 84(4):425-439. PubMed ID: 38478331
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological interventions for non-alcoholic fatty liver disease: a systematic review and network meta-analysis.
Sridharan K; Sivaramakrishnan G; Sequeira RP; Elamin A
Postgrad Med J; 2018 Oct; 94(1116):556-565. PubMed ID: 30341231
[TBL] [Abstract][Full Text] [Related]
9. REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis.
Ratziu V; Sanyal AJ; Loomba R; Rinella M; Harrison S; Anstee QM; Goodman Z; Bedossa P; MacConell L; Shringarpure R; Shah A; Younossi Z
Contemp Clin Trials; 2019 Sep; 84():105803. PubMed ID: 31260793
[TBL] [Abstract][Full Text] [Related]
10. Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: A network meta-analysis.
Park MJ; Kim H; Kim MG; Kim K
Clin Mol Hepatol; 2023 Jul; 29(3):693-704. PubMed ID: 36907574
[TBL] [Abstract][Full Text] [Related]
11. Medical and Surgical Treatment Options for Nonalcoholic Steatohepatitis.
Corey KE; Rinella ME
Dig Dis Sci; 2016 May; 61(5):1387-97. PubMed ID: 26942734
[TBL] [Abstract][Full Text] [Related]
12. Treatment Strategies for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.
Golabi P; Bush H; Younossi ZM
Clin Liver Dis; 2017 Nov; 21(4):739-753. PubMed ID: 28987260
[TBL] [Abstract][Full Text] [Related]
13. Vitamin E has a beneficial effect on nonalcoholic fatty liver disease: a meta-analysis of randomized controlled trials.
Sato K; Gosho M; Yamamoto T; Kobayashi Y; Ishii N; Ohashi T; Nakade Y; Ito K; Fukuzawa Y; Yoneda M
Nutrition; 2015; 31(7-8):923-30. PubMed ID: 26059365
[TBL] [Abstract][Full Text] [Related]
14. Haptoglobin Genotype and Vitamin E Versus Placebo for the Treatment of Nondiabetic Patients with Nonalcoholic Steatohepatitis in China: A Multicenter, Randomized, Placebo-Controlled Trial Design.
Zang S; Chen J; Song Y; Bai L; Chen J; Chi X; He F; Sheng H; Wang J; Xie S; Xie W; Yang Y; Zhang J; Zheng M; Zou Z; Wang B; Shi J;
Adv Ther; 2018 Feb; 35(2):218-231. PubMed ID: 29411270
[TBL] [Abstract][Full Text] [Related]
15. Pharmacotherapeutic Impact on Nonalcoholic Steatohepatitis Histology: A Systematic Review and Network Meta-analysis.
Kovalic AJ
J Clin Exp Hepatol; 2022; 12(4):1057-1068. PubMed ID: 35814516
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of obeticholic acid in liver disease-A systematic review and meta-analysis.
Kulkarni AV; Tevethia HV; Arab JP; Candia R; Premkumar M; Kumar P; Sharma M; Reddy DN; Padaki NR
Clin Res Hepatol Gastroenterol; 2021 May; 45(3):101675. PubMed ID: 33722778
[TBL] [Abstract][Full Text] [Related]
17. Emerging and future therapies for nonalcoholic steatohepatitis in adults.
Mintziori G; Polyzos SA
Expert Opin Pharmacother; 2016 Oct; 17(14):1937-46. PubMed ID: 27564402
[TBL] [Abstract][Full Text] [Related]
18. Vitamin E and nonalcoholic fatty liver disease.
Pacana T; Sanyal AJ
Curr Opin Clin Nutr Metab Care; 2012 Nov; 15(6):641-8. PubMed ID: 23075940
[TBL] [Abstract][Full Text] [Related]
19. The efficacy of novel metabolic targeted agents and natural plant drugs for nonalcoholic fatty liver disease treatment: A PRISMA-compliant network meta-analysis of randomized controlled trials.
Zhou J; Chen Y; Yu J; Li T; Lu Z; Chen Y; Zhang X; Ye F
Medicine (Baltimore); 2021 Mar; 100(12):e24884. PubMed ID: 33761646
[TBL] [Abstract][Full Text] [Related]
20. Pharmacotherapy of nonalcoholic steatohepatitis: Reflections on the existing evidence.
Tang JT; Mao YM
J Dig Dis; 2017 Nov; 18(11):607-617. PubMed ID: 29106066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
